213 related articles for article (PubMed ID: 37078628)
21. Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies).
Brureau L; Emeville E; Multigner L; Blanchet P
Prog Urol; 2018 Jun; 28(8-9):442-449. PubMed ID: 29789237
[TBL] [Abstract][Full Text] [Related]
22. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
Inoue H; Nishimura K; Yamaguchi S; Nonomura N; Hara T
Int J Clin Oncol; 2015 Feb; 20(1):171-5. PubMed ID: 24652165
[TBL] [Abstract][Full Text] [Related]
24. Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort.
Lonergan PE; Cowan JE; Washington SL; Greenberg SA; Nguyen HG; Carroll PR
Prostate; 2021 Sep; 81(13):1009-1017. PubMed ID: 34288004
[TBL] [Abstract][Full Text] [Related]
25. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
26. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
[TBL] [Abstract][Full Text] [Related]
27. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
28. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy.
Hernández Hernández C; Kim Lee D; Sanchez Pérez M; Escobar SH
Clin Genitourin Cancer; 2019 Jun; 17(3):e645-e649. PubMed ID: 31097389
[TBL] [Abstract][Full Text] [Related]
30. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.
Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K
ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003
[TBL] [Abstract][Full Text] [Related]
31. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
[TBL] [Abstract][Full Text] [Related]
32. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients.
Yoshida T; Nakayama M; Takeda K; Arai Y; Kakimoto K; Nishimura K
Urol Int; 2012; 89(1):45-51. PubMed ID: 22441013
[TBL] [Abstract][Full Text] [Related]
33. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
34. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
35. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.
Cooperberg MR; Hilton JF; Carroll PR
Cancer; 2011 Nov; 117(22):5039-46. PubMed ID: 21647869
[TBL] [Abstract][Full Text] [Related]
36. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
37. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
38. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
Greenberg SA; Washington SL; Lonergan PE; Cowan JE; Baskin AS; Nguyen HG; Odisho AY; Simko JP; Carroll PR
J Urol; 2021 Sep; 206(3):706-714. PubMed ID: 33905262
[TBL] [Abstract][Full Text] [Related]
39. A novel nomogram provides improved accuracy for predicting biochemical recurrence after radical prostatectomy.
Xia HZ; Bi H; Yan Y; Yang B; Ma RZ; He W; Zhu XH; Zhang ZY; Zhang YT; Ma LL; Hou XF; Wirth GJ; Lu J
Chin Med J (Engl); 2021 Jun; 134(13):1576-1583. PubMed ID: 34133352
[TBL] [Abstract][Full Text] [Related]
40. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
Cooperberg MR; Broering JM; Carroll PR
J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
